Overweight and obesity Management
บทคัดย่อ
No available
References
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985-3023.
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102-38.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
Garvey WT, Garber AJ, Mechanick JI, et al. American association of clinical endocrinologists and american college of endocrinology position statement
on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocrine Practice : official journal of the American College of Endocrinology
and the American Association of Clinical Endocrinologists. 2014;20:977-89.
Garvey WT, Garber AJ, Mechanick JI, et al. American association of clinical endocrinologists and american college of endocrinology consensus conference
on obesity: building an evidence base for comprehensive action. Endocrine Practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2014;20:956-76.
Obesity: Identification, Assessment and Management of Overweight and Obesity in Children, Young People and Adults: Partial Update of CG43. London; 2014.
Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111-20.
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol
Metab. 2015;100:342-62.
Da Silva JA, Jacobs JW, Bijlsma JW. Revisiting the toxicity of low-dose glucocorticoids: risks and fears. Ann NY Acad Sci. 2006;1069:275-88.
Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity. 2010; 18:2398-400.
Weintraub M, Sundaresan PR, Schuster B, et al. Longterm weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus
phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51:595-601.
Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed dur-ing long-term treatment of obesity. Intern J Obesity.
;38:292-8.
OûNeil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOMDM
study. Obesity. 2012;20:1426-36.
Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes. 2005;29:517-23.
Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and
overweight adults (SEQUEL): a randomized, placebocontrolled, phase 3 extension study. Am J Clin Nutr.2012;95:297-308.
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-52.
Garvey WT, Ryan DH, Bohannon NJ, et al. Weightloss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care.
;37:3309-16.
Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the oncedaily oncedaily human GLP-1 analog, liraglutide. Intern J Obes 2012;36:843-54.
Fried M, Hainer V, Basdevant A, et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes. 2007;31:569-77.
Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol / European Federation of Endocrine Societies. 2008;158:135-45.
DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176-83.
Restrictive surgery for weight loss. Accees from: http://www.webmd.com/diet/weight-loss-surgery/restrictive-surgery วันที่ 26 มิถุนายน 2556.
Biliopancreatic diversion at NJ bariatrics. Accees from:http://www.njbariatricspc.com/bariatric-surgerytypes/biliopancreatic-diversion-nj/2556.
Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219-34.
Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA: the journal of the American Medical Association
;307:56-65.
Maggard MA, Shugarman LR, Suttorp M, et al. Metaanalysis: surgical treatment of obesity. Ann Intern Med 2005;142:547-59.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA : the journal of the American Medical Association
;292:1724-37.
Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-52.
Downloads
เผยแพร่แล้ว
How to Cite
ฉบับ
บท
License
เนื้อหาและข้อมูลในบทความที่ตีพิมพ์ลงใน Thai JPEN วารสารโภชนบำบัด ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสารไม่จำเป็นต้องเห็นด้วยหรือร่วมรับผิดชอบใด ๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ใน Thai JPEN วารสารโภชนบำบัด ถือเป็นลิขสิทธิ์ของ Thai JPEN วารสารโภชนบำบัด หากบุคคลหรืหน่วยงานใดต้องการนำทั้งหมดหรือส่วนใดส่วนหนึ่งไปเผยแพร่หรือเพื่อกระทำการใด จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษรจาก Thai JPEN วารสารโภชนบำบัด ก่อนเท่านั้น
